ral events in the near horizon that could boost Veru's profile and make a good case for early entry into sharing its business to reap benefits. For Tamsulosin DRS/XR, we could see completion of the final bioequivalence study, followed by an NDA for US and a Marketing Authorizing Application (for UK) submission,